Onco-Innovations Limited (ONNVF)

Market Cap	19.59M -72.5%
Revenue (ttm)	64.78K +7.2%
Net Income	-8.18M
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,375
Open	0.2674
Previous Close	0.2958
Day's Range	0.2674 - 0.2949
52-Week Range	0.2674 - 1.1900
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Sep 28, 2026

About Onco-Innovations

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company’s lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3′-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. In addition, the company engages in research and development activities...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Thomas O’Shaughnessy
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: ONNVF

Financial Performance

In fiscal year 2026, Onco-Innovations's revenue was 110,378, an increase of 69.06% compared to the previous year's 65,291. Losses were -10.78 million, 42.5% more than in 2025.

Financial numbers in CAD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 26, 2026

Data Sources Report a data error